Recent News

• 09.22.2025 - IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
• 09.19.2025 - IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research
• 09.02.2025 - IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
• 08.28.2025 - IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
• 08.05.2025 - IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call
• 08.05.2025 - Imunon Second Quarter 2025 Financial Results

Recent Filings

• 09.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.28.2025 - EX-99.1 EX-99.1
• 08.28.2025 - 8-K Current report
• 08.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.06.2025 - 4 Statement of changes in beneficial ownership of securities